Platelet derivative compositions, and methods of making and using such compositions

A platelet derivative composition in a vial, comprising

• a population of platelet derivatives having a compromised plasma membrane and a reduced propensity to aggregate as compared to platelets under in vitro aggregation conditions consisting of 1 mg/ml ristocetin, a buffer, and citrated plasma, as measured by light transmission aggregometry 5 minutes after ristocetin addition, such that no more than 5% of the platelet derivatives in the population aggregate under the in vitro aggregation conditions,
• wherein the platelet derivative composition in the vial is present in a volume of at least 10 ml, and
• wherein the platelet derivatives in the platelet derivative composition:
• have a CD41 positivity of at least 70% when measured using flow cytometry,
• have a phosphatidylserine positivity of at least 70%, when measured using Annexin V binding in flow cytometry,
• have less than 4.5% microparticles,
• have less than 2% crosslinking of platelet membranes via proteins and/or lipids present on the membranes,
• are capable of generating thrombin in an in vitro thrombin formation assay,
• are capable of producing occlusion by attaining a pressure of 80 kPa in less than 14 minutes when used at a concentration of about 70×103 platelet derivatives/μl in platelet-reduced citrated whole blood in an in vitro total thrombus-formation analysis system (T-TAS), and
• have a concentration of at least 5,250×103 platelet derivatives/μl.